<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7291320\results\search\disease\results.xml">
  <result pre="(CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract The recent outbreak of coronavirus" exact="disease" post="2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus"/>
  <result pre="recent outbreak of coronavirus disease 2019 (COVID-19) caused by severe" exact="acute" post="respiratory syndrome coronavirus 2 has been declared a public"/>
  <result pre="outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute" exact="respiratory" post="syndrome coronavirus 2 has been declared a public health"/>
  <result pre="of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory" exact="syndrome" post="coronavirus 2 has been declared a public health emergency"/>
  <result pre="public health emergency of international concern. COVID-19 may present as" exact="acute" post="respiratory distress syndrome in severe cases, and patients with"/>
  <result pre="health emergency of international concern. COVID-19 may present as acute" exact="respiratory" post="distress syndrome in severe cases, and patients with pre-existing"/>
  <result pre="of international concern. COVID-19 may present as acute respiratory distress" exact="syndrome" post="in severe cases, and patients with pre-existing cardiovascular comorbidities"/>
  <result pre="respiratory distress syndrome in severe cases, and patients with pre-existing" exact="cardiovascular" post="comorbidities are reported to be the most vulnerable. Notably,"/>
  <result pre="cardiovascular comorbidities are reported to be the most vulnerable. Notably," exact="acute" post="myocardial injury, determined by elevated high-sensitivity troponin levels, is"/>
  <result pre="with mortality. Therefore, understanding the effects of COVID-19 on the" exact="cardiovascular" post="system is essential for providing comprehensive medical care for"/>
  <result pre="review, we summarize the rapidly evolving data and highlight the" exact="cardiovascular" post="considerations related to COVID-19. COVID-19 cardiovascular disease myocardial injury"/>
  <result pre="data and highlight the cardiovascular considerations related to COVID-19. COVID-19" exact="cardiovascular disease" post="myocardial injury 1. Introduction In December 2019, coronavirus disease"/>
  <result pre="and highlight the cardiovascular considerations related to COVID-19. COVID-19 cardiovascular" exact="disease" post="myocardial injury 1. Introduction In December 2019, coronavirus disease"/>
  <result pre="cardiovascular disease myocardial injury 1. Introduction In December 2019, coronavirus" exact="disease" post="2019 (COVID-19) infected pneumonia caused by severe acute respiratory"/>
  <result pre="1. Introduction In December 2019, coronavirus disease 2019 (COVID-19) infected" exact="pneumonia" post="caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)"/>
  <result pre="2019, coronavirus disease 2019 (COVID-19) infected pneumonia caused by severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) occurred in Wuhan, China"/>
  <result pre="coronavirus disease 2019 (COVID-19) infected pneumonia caused by severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) occurred in Wuhan, China with"/>
  <result pre="disease 2019 (COVID-19) infected pneumonia caused by severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) occurred in Wuhan, China with further"/>
  <result pre="worldwide transmission to a pandemic outbreak. An initial cluster of" exact="infections" post="was linked to the Huanan seafood market, potentially due"/>
  <result pre="to animal contact [1]. Subsequently, human-to-human transmission occurred, and the" exact="disease" post="rapidly spread to people around the globe. As of"/>
  <result pre="numbers continue to rise [2]. SARS-CoV-2 can cause multiple system" exact="infections" post="in various animals and mainly respiratory tract infections in"/>
  <result pre="can cause multiple system infections in various animals and mainly" exact="respiratory" post="tract infections in humans, such as severe acute respiratory"/>
  <result pre="multiple system infections in various animals and mainly respiratory tract" exact="infections" post="in humans, such as severe acute respiratory syndrome (SARS)"/>
  <result pre="and mainly respiratory tract infections in humans, such as severe" exact="acute" post="respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS)"/>
  <result pre="mainly respiratory tract infections in humans, such as severe acute" exact="respiratory" post="syndrome (SARS) and Middle East respiratory syndrome (MERS) [3]."/>
  <result pre="respiratory tract infections in humans, such as severe acute respiratory" exact="syndrome" post="(SARS) and Middle East respiratory syndrome (MERS) [3]. The"/>
  <result pre="such as severe acute respiratory syndrome (SARS) and Middle East" exact="respiratory" post="syndrome (MERS) [3]. The majority of patients have mild"/>
  <result pre="as severe acute respiratory syndrome (SARS) and Middle East respiratory" exact="syndrome" post="(MERS) [3]. The majority of patients have mild symptoms,"/>
  <result pre="patients have mild symptoms, but some patients progress rapidly with" exact="acute" post="respiratory distress syndrome (ARDS) and shock, which are followed"/>
  <result pre="have mild symptoms, but some patients progress rapidly with acute" exact="respiratory" post="distress syndrome (ARDS) and shock, which are followed by"/>
  <result pre="symptoms, but some patients progress rapidly with acute respiratory distress" exact="syndrome" post="(ARDS) and shock, which are followed by multiple organ"/>
  <result pre="symptoms in the early stage are fever, fatigue, cough, and" exact="muscle" post="ache [3,4], COVID-19 often enters the differential diagnosis of"/>
  <result pre="often enters the differential diagnosis of dyspnea at rest and" exact="chest" post="pain, which requires engagement of cardiovascular (CV) specialists [5,6]."/>
  <result pre="dyspnea at rest and chest pain, which requires engagement of" exact="cardiovascular" post="(CV) specialists [5,6]. Moreover, COVID-19 patients with pre-existing cardiovascular"/>
  <result pre="of cardiovascular (CV) specialists [5,6]. Moreover, COVID-19 patients with pre-existing" exact="cardiovascular disease" post="(CVD) have been reported to be at high risk"/>
  <result pre="cardiovascular (CV) specialists [5,6]. Moreover, COVID-19 patients with pre-existing cardiovascular" exact="disease" post="(CVD) have been reported to be at high risk"/>
  <result pre="CV complications [7]. Remarkably, recent retrospective studies have demonstrated that" exact="acute" post="myocardial injury is a common condition among patients with"/>
  <result pre="common condition among patients with COVID-19 and is associated with" exact="disease" post="severity and mortality [8,9]. Finally, several therapeutics for COVID-19"/>
  <result pre="are distributed broadly among humans and cause respiratory, hepatic, and" exact="neurologic disease" post="[10]. Until recently, six different coronavirus strains were known"/>
  <result pre="distributed broadly among humans and cause respiratory, hepatic, and neurologic" exact="disease" post="[10]. Until recently, six different coronavirus strains were known"/>
  <result pre="in immunocompetent individuals [11]. The two other strains include severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome"/>
  <result pre="immunocompetent individuals [11]. The two other strains include severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus"/>
  <result pre="individuals [11]. The two other strains include severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV),"/>
  <result pre="include severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV), which are zoonotic in origin and"/>
  <result pre="severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV), which are zoonotic in origin and have"/>
  <result pre="The virus is thought to spread mainly from human-to-human through" exact="respiratory" post="droplets produced by an infected individual [14]. Studies have"/>
  <result pre="have demonstrated that SARS-CoV-2, as well as SARS-CoV, binds its" exact="viral" post="spike (S) proteins to angiotensin-converting enzyme 2 (ACE2) proteins"/>
  <result pre="[12,15,16,17]. ACE2 is highly expressed in lung alveolar cells (principally" exact="type II" post="alveolar cells) and serves a role in lung protection;"/>
  <result pre="alveolar cells) and serves a role in lung protection; therefore," exact="viral" post="binding to this receptor deregulates a lung protective pathway,"/>
  <result pre="to this receptor deregulates a lung protective pathway, contributing to" exact="viral" post="pathogenicity [18,19]. 3. Epidemiology and Clinical Features of COVID-19"/>
  <result pre="Epidemiology and Clinical Features of COVID-19 Since December 2019, the" exact="disease" post="has spread over 180 countries across the world [2]."/>
  <result pre="to be higher than seasonal influenza (less than 0.1%) and" exact="lower" post="than SARS (9%) and MERS (36%) [11]. The basic"/>
  <result pre="[22]. This estimates that each COVID-19 patient has been spreading" exact="infection" post="to 2.2 other people. Another important reason for the"/>
  <result pre="the Diamond Princess cruise ship [24]. Unlike SARS-CoV, the detected" exact="viral" post="load is similar in the asymptomatic and symptomatic patients"/>
  <result pre="the detected viral load is similar in the asymptomatic and" exact="symptomatic" post="patients with COVID-19, which suggests potential transmission of the"/>
  <result pre="suggests potential transmission of the virus from asymptomatic or mild" exact="symptomatic" post="patients to other people [25,26]. Fever is the most"/>
  <result pre="from asymptomatic or mild symptomatic patients to other people [25,26]." exact="Fever" post="is the most common symptom (88.7%) but it can"/>
  <result pre="can be present in only 43.8% on admission [27]. Since" exact="absence of" post="fever in COVID-19 is more frequent than in SARS-CoV"/>
  <result pre="symptom is cough (67.8%), while nausea or vomiting (5.0%) and" exact="diarrhea" post="(3.8%) are uncommon. The median incubation period has been"/>
  <result pre="The most common radiographic findings are ground-glass opacity (56%) and" exact="bilateral" post="patch shadowing (52%) on computed tomography (CT) [27]. Electrocardiogram"/>
  <result pre="tests, lymphocytopenia is commonly observed (83%) and most patients have" exact="elevated serum" post="levels of C-reactive protein and proinflammatory cytokines [7,10]. In"/>
  <result pre="was mild (no or mild pneumonia) in 81%, severe (dyspnea," exact="respiratory" post="frequency â‰¥30/min, blood oxygen saturation â‰¤93%, partial pressure of"/>
  <result pre="81%, severe (dyspnea, respiratory frequency â‰¥30/min, blood oxygen saturation â‰¤93%," exact="partial" post="pressure of arterial oxygen to fraction of inspired oxygen"/>
  <result pre="within 24 to 48 h) in 14%, critical (respiratory failure," exact="septic shock," post="and/or multiple organ dysfunction or failure) in 5% of"/>
  <result pre="patients aged 80 years and older and with pre-existing CVD," exact="diabetes" post="(DM), chronic respiratory disease, hypertension (HT), and cancer [32,33]."/>
  <result pre="80 years and older and with pre-existing CVD, diabetes (DM)," exact="chronic" post="respiratory disease, hypertension (HT), and cancer [32,33]. Cases aged"/>
  <result pre="years and older and with pre-existing CVD, diabetes (DM), chronic" exact="respiratory" post="disease, hypertension (HT), and cancer [32,33]. Cases aged 70"/>
  <result pre="older and with pre-existing CVD, diabetes (DM), chronic respiratory disease," exact="hypertension" post="(HT), and cancer [32,33]. Cases aged 70 to 79"/>
  <result pre="pre-existing CVD, diabetes (DM), chronic respiratory disease, hypertension (HT), and" exact="cancer" post="[32,33]. Cases aged 70 to 79 years had an"/>
  <result pre="numbers of reports from the United States (U.S.) have linked" exact="obesity" post="to more severe COVID-19 illness and death [34,35,36]. Currently,"/>
  <result pre="world, which may find optimal treatments for COVID-19. 4. Cardiovascular" exact="Disease" post="in Patients with COVID-19 4.1. Prevalence of Cardiovascular Disease"/>
  <result pre="Cardiovascular Disease in Patients with COVID-19 4.1. Prevalence of Cardiovascular" exact="Disease" post="in COVID-19 Patients Previous studies have shown that CVD"/>
  <result pre="series including 144 patients with SARS examined the prevalence of" exact="cardiac disease," post="DM, and cancer to be 8%, 11%, and 6%,"/>
  <result pre="with SARS examined the prevalence of cardiac disease, DM, and" exact="cancer" post="to be 8%, 11%, and 6%, respectively [40]. In"/>
  <result pre="patients died in this cohort and 30% of them had" exact="ischemic heart disease," post="35.5% had DM, 24.5% had atrial fibrillation, and 9.6%"/>
  <result pre="died in this cohort and 30% of them had ischemic" exact="heart" post="disease, 35.5% had DM, 24.5% had atrial fibrillation, and"/>
  <result pre="them had ischemic heart disease, 35.5% had DM, 24.5% had" exact="atrial fibrillation," post="and 9.6% had a history of stroke [33]. The"/>
  <result pre="24.5% had atrial fibrillation, and 9.6% had a history of" exact="stroke" post="[33]. The high proportion of older patients with COVID-19"/>
  <result pre="CVD [44]. 4.2. Outcomes of COVID-19 Patients with Pre-Existing Cardiovascular" exact="Disease" post="A number of studies in the available literature suggest"/>
  <result pre="= 0.0051), HT (48% vs. 23%, p = 0.0008), and" exact="coronary artery disease" post="(CAD) (24% vs. 1%, p &amp;lt; 0.0001) than survivors"/>
  <result pre="0.0051), HT (48% vs. 23%, p = 0.0008), and coronary" exact="artery disease" post="(CAD) (24% vs. 1%, p &amp;lt; 0.0001) than survivors"/>
  <result pre="HT (48% vs. 23%, p = 0.0008), and coronary artery" exact="disease" post="(CAD) (24% vs. 1%, p &amp;lt; 0.0001) than survivors"/>
  <result pre="1099 patients with COVID-19 identified that patients who had severe" exact="disease" post="were likely to have an increased rate of any"/>
  <result pre="5.7%), HT (23.7% vs. 13.4%), CAD (5.8% vs. 1.8%), and" exact="cerebrovascular disease" post="(2.3% vs. 1.2%) [27]. Increased case fatality rates in"/>
  <result pre="HT (23.7% vs. 13.4%), CAD (5.8% vs. 1.8%), and cerebrovascular" exact="disease" post="(2.3% vs. 1.2%) [27]. Increased case fatality rates in"/>
  <result pre="(5.8% vs. 1.8%), and cerebrovascular disease (2.3% vs. 1.2%) [27]." exact="Increased" post="case fatality rates in the previously referenced analysis of"/>
  <result pre="system [45] may be crucial for the severity of COVID-19." exact="Chronic" post="diseases such as HT and DM also correspond with"/>
  <result pre="impairing macrophage and lymphocyte function [46] and may confer increased" exact="susceptibility to" post="disease complications. In sum, prevalent CVD may be a"/>
  <result pre="and lymphocyte function [46] and may confer increased susceptibility to" exact="disease" post="complications. In sum, prevalent CVD may be a marker"/>
  <result pre="COVID-19. An increased rate of adverse CVD events following COVID-19" exact="infection" post="might also play a role in prognosis, similar to"/>
  <result pre="might also play a role in prognosis, similar to other" exact="viral" post="infections, such as influenza [47,48]. 5. Cardiovascular Complications Following"/>
  <result pre="high inflammatory burden of COVID-19, significant CV complications with COVID-19" exact="infection" post="are expected. Previous reports have suggested that COVID-19 leads"/>
  <result pre="described in Table 2 and Figure 1. 5.1. Myocardial Injury" exact="Elevated" post="cardiac biomarkers have been identified in COVID-19 patients, especially"/>
  <result pre="cardiac involvement as a complication associated with COVID-19, even without" exact="respiratory" post="symptoms [30,52]. Myocardial injury, defined as elevated cardiac biomarkers,"/>
  <result pre="found that at least 8% of the patients suffered from" exact="acute" post="myocardial injury and the risk of myocardial injury was"/>
  <result pre="Myocardial injury can occur due to nonischemic myocardial process or" exact="myocardial ischemia." post="As a nonischemic myocardial factor, myocarditis and stress cardiomyopathy"/>
  <result pre="myocardial process or myocardial ischemia. As a nonischemic myocardial factor," exact="myocarditis" post="and stress cardiomyopathy may make a significant contribution in"/>
  <result pre="myocardial ischemia. As a nonischemic myocardial factor, myocarditis and stress" exact="cardiomyopathy" post="may make a significant contribution in acute myocardial injury"/>
  <result pre="myocarditis and stress cardiomyopathy may make a significant contribution in" exact="acute" post="myocardial injury of COVID-19 patients. In SARS, Oudit et"/>
  <result pre="COVID-19 patients. In SARS, Oudit et al. demonstrated that SARS-CoV" exact="viral" post="ribonucleic acid (RNA), macrophage infiltration, and myocardial damage were"/>
  <result pre="myocardial damage were detected simultaneously in 35% of autopsied human" exact="heart" post="samples from SARS patients [53]. They confirmed their findings"/>
  <result pre="from SARS patients [53]. They confirmed their findings by inducing" exact="pulmonary" post="infection with human SARS-CoV in mice, which led to"/>
  <result pre="SARS patients [53]. They confirmed their findings by inducing pulmonary" exact="infection" post="with human SARS-CoV in mice, which led to ACE2-dependent"/>
  <result pre="with human SARS-CoV in mice, which led to ACE2-dependent myocardial" exact="infection" post="in the heart. Likewise, an acute myocarditis in MERS"/>
  <result pre="led to ACE2-dependent myocardial infection in the heart. Likewise, an" exact="acute" post="myocarditis in MERS has also been proved by cardiac"/>
  <result pre="to ACE2-dependent myocardial infection in the heart. Likewise, an acute" exact="myocarditis" post="in MERS has also been proved by cardiac magnetic"/>
  <result pre="the late increase of hs-cTnI in nonsurvivors (day 16 after" exact="disease" post="onset) showed a similar trend to inflammatory markers, including"/>
  <result pre="and lactate dehydrogenase. This kinetics may reflect cytokine storms and" exact="systemic" post="inflammatory response syndrome, which provide a possible mechanism for"/>
  <result pre="systemic inflammatory response syndrome, which provide a possible mechanism for" exact="acute" post="myocardial injury due to myocarditis or stress-cardiomyopathy [44,56]. A"/>
  <result pre="provide a possible mechanism for acute myocardial injury due to" exact="myocarditis" post="or stress-cardiomyopathy [44,56]. A recent case report by Tavassi"/>
  <result pre="recent case report by Tavassi et al. suggested that the" exact="heart" post="can be directly involved in the viral infection by"/>
  <result pre="suggested that the heart can be directly involved in the" exact="viral infection" post="by SARS-CoV-2 [57]. Endocardial biopsy from a COVID-19 patient"/>
  <result pre="that the heart can be directly involved in the viral" exact="infection" post="by SARS-CoV-2 [57]. Endocardial biopsy from a COVID-19 patient"/>
  <result pre="by SARS-CoV-2 [57]. Endocardial biopsy from a COVID-19 patient with" exact="acute" post="myocardial injury demonstrated low-grade myocardial inflammation and viral particles"/>
  <result pre="patient with acute myocardial injury demonstrated low-grade myocardial inflammation and" exact="viral" post="particles in interstitial cytopathic macrophages and their surroundings, but"/>
  <result pre="a typical case of takotsubo myocardiopathy in COVID-19 patient with" exact="acute" post="myocardial injury [58]. Altogether, these findings suggest that an"/>
  <result pre="acute myocardial injury [58]. Altogether, these findings suggest that an" exact="acute" post="myocardial injury in SARS-CoV-2 infection may occur as the"/>
  <result pre="these findings suggest that an acute myocardial injury in SARS-CoV-2" exact="infection" post="may occur as the disease severity advance by cytokine"/>
  <result pre="acute myocardial injury in SARS-CoV-2 infection may occur as the" exact="disease" post="severity advance by cytokine storms and systemic inflammation or"/>
  <result pre="occur as the disease severity advance by cytokine storms and" exact="systemic" post="inflammation or viral infection to the myocardium. Several COVID-19"/>
  <result pre="disease severity advance by cytokine storms and systemic inflammation or" exact="viral infection" post="to the myocardium. Several COVID-19 cases were reported to"/>
  <result pre="severity advance by cytokine storms and systemic inflammation or viral" exact="infection" post="to the myocardium. Several COVID-19 cases were reported to"/>
  <result pre="to have cardiac symptoms at admission and diagnosed as fulminant" exact="myocarditis" post="[59,60]. However, based on current available, but limited, data,"/>
  <result pre="current available, but limited, data, the incidence of isolated fulminant" exact="myocarditis" post="appears to be low. Lessons from the previous influenza"/>
  <result pre="be low. Lessons from the previous influenza epidemics suggest that" exact="viral" post="infections can trigger acute coronary syndromes [61]. In a"/>
  <result pre="low. Lessons from the previous influenza epidemics suggest that viral" exact="infections" post="can trigger acute coronary syndromes [61]. In a limited"/>
  <result pre="the previous influenza epidemics suggest that viral infections can trigger" exact="acute" post="coronary syndromes [61]. In a limited study of 75"/>
  <result pre="viral infections can trigger acute coronary syndromes [61]. In a" exact="limited" post="study of 75 patients hospitalized with SARS, acute myocardial"/>
  <result pre="In a limited study of 75 patients hospitalized with SARS," exact="acute" post="myocardial infarction was the cause of death in two"/>
  <result pre="a limited study of 75 patients hospitalized with SARS, acute" exact="myocardial infarction" post="was the cause of death in two of five"/>
  <result pre="in two of five fatal cases [26]. Although reports of" exact="type 1" post="myocardial infarction in the setting of COVID-19 are yet"/>
  <result pre="of five fatal cases [26]. Although reports of type 1" exact="myocardial infarction" post="in the setting of COVID-19 are yet to be"/>
  <result pre="profound inflammatory response and hemodynamic changes associated with such severe" exact="disease" post="may confer an increased risk for atherosclerotic plaque rupture"/>
  <result pre="Moreover, the imbalance of oxygen supply and demand in the" exact="heart" post="(type 2 myocardial infarction) may also play a partial"/>
  <result pre="the heart (type 2 myocardial infarction) may also play a" exact="partial" post="role in the myocardial ischemia of COVID-19 patients. Several"/>
  <result pre="myocardial infarction) may also play a partial role in the" exact="myocardial ischemia" post="of COVID-19 patients. Several studies indicated that acute myocardial"/>
  <result pre="infarction) may also play a partial role in the myocardial" exact="ischemia" post="of COVID-19 patients. Several studies indicated that acute myocardial"/>
  <result pre="the myocardial ischemia of COVID-19 patients. Several studies indicated that" exact="acute" post="myocardial injury was observed in patients who required oxygen"/>
  <result pre="Those patients may have hypoxemia or hypotension along with intense" exact="systemic" post="inflammation, which may cause an oxygen supply and demand"/>
  <result pre="may cause an oxygen supply and demand imbalance in the" exact="heart" post="[20,42,62], especially when underlying CAD exists. Two recent clinical"/>
  <result pre="Two recent clinical studies clarified the characteristics of patients having" exact="acute" post="myocardial injury. In one cohort of 187 patients from"/>
  <result pre="presence of underlying CAD (32.7% vs. 3.0%, p &amp;lt; 0.001)," exact="cardiomyopathy" post="(15.4% vs. 0%, p &amp;lt; 0.001), and CV risk"/>
  <result pre="Likewise, another cohort study including 416 Chinese patients suggested that" exact="chest" post="pain at admission (13.4% vs. 0.9%, p &amp;lt; 0.001),"/>
  <result pre="&amp;lt; 0.001), CAD (29.3% vs. 6.0%, p &amp;lt; 0.001), and" exact="chronic" post="heart failure (14.6% vs. 1.5%, p &amp;lt; 0.001) were"/>
  <result pre="0.001), CAD (29.3% vs. 6.0%, p &amp;lt; 0.001), and chronic" exact="heart" post="failure (14.6% vs. 1.5%, p &amp;lt; 0.001) were more"/>
  <result pre="it is rational to presume that patients with CAD or" exact="heart" post="failure are susceptible to cardiac injury, and once such"/>
  <result pre="injury, and once such patients are infected with severe pneumonia," exact="myocardial ischemia" post="or cardiac dysfunction are more likely to occur, ultimately"/>
  <result pre="and once such patients are infected with severe pneumonia, myocardial" exact="ischemia" post="or cardiac dysfunction are more likely to occur, ultimately"/>
  <result pre="likely to occur, ultimately leading to a sudden deterioration. Microvascular" exact="thrombosis" post="in small coronary vessels due to disseminated intravascular coagulation"/>
  <result pre="sudden deterioration. Microvascular thrombosis in small coronary vessels due to" exact="disseminated intravascular coagulation" post="is another potential but unproven mechanism that may contribute"/>
  <result pre="that troponin levels can also be exacerbated in patients with" exact="renal insufficiency" post="due to delayed excretion, which is common in patients"/>
  <result pre="nature of abnormal troponin results among patients with COVID-19, the" exact="American" post="College of Cardiology states that â€œabnormal troponin should not"/>
  <result pre="that â€œabnormal troponin should not be considered evidence for an" exact="acute" post="myocardial infarction without corroborating evidenceâ€� [64]. Comprehensive assessments by"/>
  <result pre="â€œabnormal troponin should not be considered evidence for an acute" exact="myocardial infarction" post="without corroborating evidenceâ€� [64]. Comprehensive assessments by electrocardiograms, echocardiograms,"/>
  <result pre="magnetic resonance image [52,65], and other cardiac biomarkers, such as" exact="brain" post="natriuretic peptide (BNP), may help detect early warnings and"/>
  <result pre="Unfortunately, until now, no specific treatments have been recommended for" exact="acute" post="myocardial injury in patients with COVID-19. However, it may"/>
  <result pre="prioritized treatment and even more aggressive treatment strategies. 5.2. Decompensated" exact="Heart Failure" post="and Mixed Shock The prevalence of new-onset heart failure"/>
  <result pre="treatment and even more aggressive treatment strategies. 5.2. Decompensated Heart" exact="Failure" post="and Mixed Shock The prevalence of new-onset heart failure"/>
  <result pre="even more aggressive treatment strategies. 5.2. Decompensated Heart Failure and" exact="Mixed" post="Shock The prevalence of new-onset heart failure during COVID-19"/>
  <result pre="more aggressive treatment strategies. 5.2. Decompensated Heart Failure and Mixed" exact="Shock" post="The prevalence of new-onset heart failure during COVID-19 associated"/>
  <result pre="Decompensated Heart Failure and Mixed Shock The prevalence of new-onset" exact="heart" post="failure during COVID-19 associated hospitalization was reported to be"/>
  <result pre="United States indicated that 33% of the ICU patients developed" exact="cardiomyopathy" post="[50]. Most recently, Fried et al. described three cases"/>
  <result pre="Most recently, Fried et al. described three cases of COVID-19" exact="infection" post="with acute systolic heart failure [30], suggesting that isolated"/>
  <result pre="Fried et al. described three cases of COVID-19 infection with" exact="acute" post="systolic heart failure [30], suggesting that isolated myocarditis, myocarditis"/>
  <result pre="et al. described three cases of COVID-19 infection with acute" exact="systolic heart failure" post="[30], suggesting that isolated myocarditis, myocarditis secondary to cytokine"/>
  <result pre="al. described three cases of COVID-19 infection with acute systolic" exact="heart" post="failure [30], suggesting that isolated myocarditis, myocarditis secondary to"/>
  <result pre="with acute systolic heart failure [30], suggesting that isolated myocarditis," exact="myocarditis" post="secondary to cytokine storm, stress-cardiomyopathy, and hypoxemia on underlying"/>
  <result pre="acute systolic heart failure [30], suggesting that isolated myocarditis, myocarditis" exact="secondary" post="to cytokine storm, stress-cardiomyopathy, and hypoxemia on underlying cardiovascular"/>
  <result pre="myocarditis secondary to cytokine storm, stress-cardiomyopathy, and hypoxemia on underlying" exact="cardiovascular disease" post="could be considered as potential mechanisms of left ventricular"/>
  <result pre="secondary to cytokine storm, stress-cardiomyopathy, and hypoxemia on underlying cardiovascular" exact="disease" post="could be considered as potential mechanisms of left ventricular"/>
  <result pre="cardiovascular disease could be considered as potential mechanisms of left" exact="ventricular dysfunction." post="However, given the scarce availability of data regarding this"/>
  <result pre="of data regarding this topic, it remains unclear whether the" exact="acute" post="heart failure following COVID-19 is mainly due to exacerbation"/>
  <result pre="data regarding this topic, it remains unclear whether the acute" exact="heart" post="failure following COVID-19 is mainly due to exacerbation of"/>
  <result pre="pre-existing cardiac dysfunction or new-onset cardiomyopathy. Since imaging features of" exact="congestive heart failure" post="in X-ray or CT resemble to those of ARDS"/>
  <result pre="cardiac dysfunction or new-onset cardiomyopathy. Since imaging features of congestive" exact="heart" post="failure in X-ray or CT resemble to those of"/>
  <result pre="or CT resemble to those of ARDS (ground-glass opacity and" exact="bilateral" post="pulmonary infiltration), echocardiography and serum BNP may help clarify"/>
  <result pre="CT resemble to those of ARDS (ground-glass opacity and bilateral" exact="pulmonary" post="infiltration), echocardiography and serum BNP may help clarify the"/>
  <result pre="BNP may help clarify the diagnosis [12]. In particular, COVID-19" exact="infection" post="can cause acute decompensated heart failure when underlying cardiovascular"/>
  <result pre="clarify the diagnosis [12]. In particular, COVID-19 infection can cause" exact="acute" post="decompensated heart failure when underlying cardiovascular disease exists and"/>
  <result pre="diagnosis [12]. In particular, COVID-19 infection can cause acute decompensated" exact="heart" post="failure when underlying cardiovascular disease exists and may lead"/>
  <result pre="COVID-19 infection can cause acute decompensated heart failure when underlying" exact="cardiovascular disease" post="exists and may lead to mixed shock [30]. Invasive"/>
  <result pre="infection can cause acute decompensated heart failure when underlying cardiovascular" exact="disease" post="exists and may lead to mixed shock [30]. Invasive"/>
  <result pre="cardiovascular disease exists and may lead to mixed shock [30]." exact="Invasive" post="hemodynamic monitoring using pulmonary artery catheterization can be helpful"/>
  <result pre="may lead to mixed shock [30]. Invasive hemodynamic monitoring using" exact="pulmonary" post="artery catheterization can be helpful to manage the cardiac"/>
  <result pre="cannulation in the context of mixed presentations of ARDS with" exact="systolic heart failure." post="Judgement will be needed to decide when and how"/>
  <result pre="in the context of mixed presentations of ARDS with systolic" exact="heart" post="failure. Judgement will be needed to decide when and"/>
  <result pre="many other factors. Lastly, providing ECMO during outbreaks of emerging" exact="infectious diseases" post="faces unique challenges. Careful planning, judicious resource allocation, and"/>
  <result pre="personnel to provide complex therapeutic interventions while adhering to strict" exact="infection" post="control measures are all crucial components of an ECMO"/>
  <result pre="all crucial components of an ECMO action plan [39]. 5.3." exact="Cardiac" post="Arrhythmia High influenza activity has been reported to increase"/>
  <result pre="crucial components of an ECMO action plan [39]. 5.3. Cardiac" exact="Arrhythmia" post="High influenza activity has been reported to increase the"/>
  <result pre="activity has been reported to increase the risk of ventricular" exact="arrhythmia" post="[68]. In a study of 121 SARS patients, tachycardia"/>
  <result pre="(72%), and other complications were hypotension (50%), bradycardia (15%), and" exact="transient" post="paroxysmal atrial fibrillation in only one patient [69]. However,"/>
  <result pre="other complications were hypotension (50%), bradycardia (15%), and transient paroxysmal" exact="atrial fibrillation" post="in only one patient [69]. However, most of these"/>
  <result pre="complications were hypotension (50%), bradycardia (15%), and transient paroxysmal atrial" exact="fibrillation" post="in only one patient [69]. However, most of these"/>
  <result pre="and these conditions were mostly self-limiting. In hospitalized COVID-19 patients," exact="cardiac arrhythmia" post="was reported in 16.7% of 138 patients and was"/>
  <result pre="these conditions were mostly self-limiting. In hospitalized COVID-19 patients, cardiac" exact="arrhythmia" post="was reported in 16.7% of 138 patients and was"/>
  <result pre="reported by Guo et al. described that higher incidence of" exact="ventricular tachycardia" post="or ventricular fibrillation was observed in patients with myocardial"/>
  <result pre="et al. described that higher incidence of ventricular tachycardia or" exact="ventricular fibrillation" post="was observed in patients with myocardial injury than those"/>
  <result pre="al. described that higher incidence of ventricular tachycardia or ventricular" exact="fibrillation" post="was observed in patients with myocardial injury than those"/>
  <result pre="myocardial injury, suggesting a strong relationship between cardiac involvement and" exact="arrhythmia" post="in patients with COVID-19 [42]. In addition, high prevalence"/>
  <result pre="in patients with COVID-19 [42]. In addition, high prevalence of" exact="arrhythmia" post="in patients with severe disease might be, in part,"/>
  <result pre="In addition, high prevalence of arrhythmia in patients with severe" exact="disease" post="might be, in part, attributable to metabolic disarray, hypoxemia,"/>
  <result pre="hypoxemia, or neurohormonal or inflammatory stress in the setting of" exact="viral infection" post="[12]. 5.4. Venous Thromboembolism Clotting and development of coagulopathy"/>
  <result pre="or neurohormonal or inflammatory stress in the setting of viral" exact="infection" post="[12]. 5.4. Venous Thromboembolism Clotting and development of coagulopathy"/>
  <result pre="inflammatory stress in the setting of viral infection [12]. 5.4." exact="Venous Thromboembolism" post="Clotting and development of coagulopathy appeared as a noxious"/>
  <result pre="viral infection [12]. 5.4. Venous Thromboembolism Clotting and development of" exact="coagulopathy" post="appeared as a noxious complication in severe and critical"/>
  <result pre="COVID-19 patients [27,70]. Early reports of critically ill patients with" exact="coagulopathy" post="showed poor prognostic features. The first hint suggesting that"/>
  <result pre="COVID-19 patients. Following several similar reports, the International Society of" exact="Thrombosis" post="and Haemostasis promptly proposed an interim guidance on recognition"/>
  <result pre="promptly proposed an interim guidance on recognition and management of" exact="coagulopathy" post="[71]. In a previously published necropsy series comprising a"/>
  <result pre="coagulopathy [71]. In a previously published necropsy series comprising a" exact="total" post="of eight SARS patients, pulmonary thromboemboluses were found in"/>
  <result pre="published necropsy series comprising a total of eight SARS patients," exact="pulmonary" post="thromboemboluses were found in four patients and three had"/>
  <result pre="pulmonary thromboemboluses were found in four patients and three had" exact="deep vein thrombosis" post="(DVT) [72]. However, given the scarce availability of data"/>
  <result pre="were found in four patients and three had deep vein" exact="thrombosis" post="(DVT) [72]. However, given the scarce availability of data"/>
  <result pre="scarce availability of data on this topic, the pathophysiology of" exact="venous thromboembolism" post="(VTE) among SARS patients have not been fully characterized."/>
  <result pre="been fully characterized. Early case reports [73,74,75] reporting DVT and/or" exact="acute" post="pulmonary embolism (APE) in COVID-19 patients paved the way"/>
  <result pre="fully characterized. Early case reports [73,74,75] reporting DVT and/or acute" exact="pulmonary embolism" post="(APE) in COVID-19 patients paved the way for more"/>
  <result pre="registry cohort of 25 COVID-19 patients in China with CT" exact="pulmonary" post="angiography suggested a high rate of thrombotic events, with"/>
  <result pre="patients are likely at increased risk of VTE. However, increased" exact="coagulopathy" post="abnormalities and thrombotic susceptibility in COVID-19 patients are far"/>
  <result pre="the scope of this review. Higher thrombotic burden in the" exact="acute" post="phase of COVID-19 relies on proinflammatory cytokine/chemokine release [78,79],"/>
  <result pre="cytokine/chemokine release [78,79], increased endothelial dysfunction/damage, and potential sepsis induced" exact="coagulopathy" post="development in severe cases, all promoting coagulation activation. Recent"/>
  <result pre="cases, all promoting coagulation activation. Recent insights found that severe" exact="lung inflammation" post="and impaired pulmonary gas exchange in COVID-19 has been"/>
  <result pre="activation. Recent insights found that severe lung inflammation and impaired" exact="pulmonary" post="gas exchange in COVID-19 has been associated with upregulation"/>
  <result pre="due to the virus binding to the ACE2 receptor promotes" exact="acute" post="inflammation and hypercoagulation, which may be of paramount importance"/>
  <result pre="with clinical deterioration, such as unexplained hemodynamic instability and hypoxemia." exact="Elevated" post="cardiac biomarkers and ST-T abnormalities may be detected in"/>
  <result pre="some cases [83,84], which can also be observed in other" exact="cardiovascular" post="complications. The only widely available treatment for VTE is"/>
  <result pre="all patients who require hospital admission for COVID-19, in the" exact="absence of" post="any contraindications [12,71]. The real incidence of VTE remains"/>
  <result pre="be paid to the danger of VTE associated with COVID-19" exact="infection" post="in clinical practice. 5.5. COVID-19 and RAAS Inhibitors ACE2,"/>
  <result pre="5.5. COVID-19 and RAAS Inhibitors ACE2, a surface molecule, is" exact="localized" post="in various human organs including oral and nasal mucosa,"/>
  <result pre="various human organs including oral and nasal mucosa, nasopharynx, lung," exact="and heart" post="[85,86,87]. In renin-angiotensin-aldosterone system (RAAS), ACE2 catalysis the conversion"/>
  <result pre="human organs including oral and nasal mucosa, nasopharynx, lung, and" exact="heart" post="[85,86,87]. In renin-angiotensin-aldosterone system (RAAS), ACE2 catalysis the conversion"/>
  <result pre="[88]. Moreover, ACE2 has been found to be protective from" exact="acute" post="lung injury and myocardial injury in animal models [86,89]."/>
  <result pre="As previously shown for SARS-CoV, SARS-CoV-2 similarly utilizes ACE2 for" exact="viral" post="cell entry [17] and after the initial engagement of"/>
  <result pre="which can exacerbate lung and myocardial injuries induced by the" exact="viral infection." post="There has been a growing concern whether the increased"/>
  <result pre="adverse outcomes of COVID-19 through upregulation of ACE2 and increase" exact="viral" post="load. In animal models, increased expression and activity of"/>
  <result pre="expression and activity of ACE2 in various organs including the" exact="heart" post="were found in connection with ACE-I and ARBs administration"/>
  <result pre="evidence providing a causal relationship between ACE2 activity and increased" exact="viral" post="load in a critical way. On the contrary, there"/>
  <result pre="abundant evidence of the mortality-lowering effects of RAAS inhibitors in" exact="CV disease." post="Abrupt withdrawal of those drugs in high-risk patients, including"/>
  <result pre="of those drugs in high-risk patients, including those who have" exact="heart" post="failure or prior myocardial infarction, may result in clinical"/>
  <result pre="high-risk patients, including those who have heart failure or prior" exact="myocardial infarction," post="may result in clinical instability and adverse outcomes. Consistently,"/>
  <result pre="to show significant reduction in 28-day mortality or diminish throat" exact="viral" post="RNA detectability compared to standard care [103]. Remdesivir is"/>
  <result pre="of hydroxychloroquine (an analogue of chloroquine) and azithromycin on the" exact="respiratory" post="viral loads in patients with COVID-19 [105]. Patients treated"/>
  <result pre="hydroxychloroquine (an analogue of chloroquine) and azithromycin on the respiratory" exact="viral" post="loads in patients with COVID-19 [105]. Patients treated with"/>
  <result pre="[105]. Patients treated with hydroxychloroquine showed a significant reduction in" exact="viral" post="carriage by day 6 compared to the control group."/>
  <result pre="of clopidogrel and prasugrel and increased serum concentration of ticagrelor." exact="Cardiac" post="side effects of chloroquine/hydroxychloroquine are rarely reported, but in"/>
  <result pre="enzyme in the myocyte which leads to conduction abnormalities and" exact="cardiomyopathy" post="[108]. Careful QT monitoring is recommended especially when a"/>
  <result pre="corticosteroid is known to cause fluid retention, electrolyte derangement, and" exact="hypertension" post="as direct CV effects. With the current COVID-19 pandemic,"/>
  <result pre="to prevent patient global deterioration. 7. Prognosis of Survivors Undergoing" exact="Respiratory" post="Virus Infection Residual systemic inflammatory and procoagulant activity can"/>
  <result pre="patient global deterioration. 7. Prognosis of Survivors Undergoing Respiratory Virus" exact="Infection" post="Residual systemic inflammatory and procoagulant activity can be observed"/>
  <result pre="deterioration. 7. Prognosis of Survivors Undergoing Respiratory Virus Infection Residual" exact="systemic" post="inflammatory and procoagulant activity can be observed in survivors"/>
  <result pre="procoagulant activity can be observed in survivors of hospitalization for" exact="pneumonia" post="long after resolution of the index infection [56]. Nevertheless,"/>
  <result pre="of hospitalization for pneumonia long after resolution of the index" exact="infection" post="[56]. Nevertheless, long-term follow-up data concerning the survivors of"/>
  <result pre="infection [56]. Nevertheless, long-term follow-up data concerning the survivors of" exact="respiratory" post="virus epidemics are scarce. An observational study previously demonstrated"/>
  <result pre="are scarce. An observational study previously demonstrated that hospitalization for" exact="pneumonia" post="was associated with increased short-term and long-term risk of"/>
  <result pre="with increased short-term and long-term risk of CVD, suggesting that" exact="pneumonia" post="may be an important risk factor for CVD [110]."/>
  <result pre="COVID-19 and is associated with a higher risk of severe" exact="disease" post="and morality. Myocardial injury and myocardiopathy are present in"/>
  <result pre="of critical cases and patients with pre-existing CAD or underlying" exact="heart" post="failure seem to be susceptible to myocardial injury. Despite"/>
  <result pre="they have no relationship to disclose. References References 1.ChanJ.F.YuanS.KokK.H.ToK.K.ChuH.YangJ.XingF.LiuJ.YipC.C.PoonR.W.et al.A" exact="familial" post="cluster of pneumonia associated with the 2019 novel coronavirus"/>
  <result pre="relationship to disclose. References References 1.ChanJ.F.YuanS.KokK.H.ToK.K.ChuH.YangJ.XingF.LiuJ.YipC.C.PoonR.W.et al.A familial cluster of" exact="pneumonia" post="associated with the 2019 novel coronavirus indicating person-to-person transmission:"/>
  <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: A descriptive studyLancet (Lond. Engl.)202039550751310.1016/S0140-6736(20)30211-7 4.WangD.HuB.HuC.ZhuF.LiuX.ZhangJ.WangB.XiangH.ChengZ.XiongY.et"/>
  <result pre="al.Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected" exact="Pneumonia" post="in Wuhan, ChinaJAMA202010.1001/jama.2020.158532031570 5.Biondi-ZoccaiG.LandoniG.CarnevaleR.CavarrettaE.SciarrettaS.FratiG.SARS-CoV-2 and COVID-19: Facing the pandemic"/>
  <result pre="5.Biondi-ZoccaiG.LandoniG.CarnevaleR.CavarrettaE.SciarrettaS.FratiG.SARS-CoV-2 and COVID-19: Facing the pandemic together as citizens and" exact="cardiovascular" post="practitionersMinerva Cardioangiol.202010.23736/s0026-4725.20.05250-0 6.HanY.ZengH.JiangH.YangY.YuanZ.ChengX.JingZ.LiuB.ChenJ.NieS.et al.CSC Expert Consensus on Principles of"/>
  <result pre="Expert Consensus on Principles of Clinical Management of Patients with" exact="Severe" post="Emergent Cardiovascular Diseases during the COVID-19 EpidemicCirculation202010.1161/CIRCULATIONAHA.120.04701132216640 7.ZhouF.YuT.DuR.FanG.LiuY.LiuZ.XiangJ.WangY.SongB.GuX.et al.Clinical"/>
  <result pre="on Principles of Clinical Management of Patients with Severe Emergent" exact="Cardiovascular Diseases" post="during the COVID-19 EpidemicCirculation202010.1161/CIRCULATIONAHA.120.04701132216640 7.ZhouF.YuT.DuR.FanG.LiuY.LiuZ.XiangJ.WangY.SongB.GuX.et al.Clinical course and risk"/>
  <result pre="Principles of Clinical Management of Patients with Severe Emergent Cardiovascular" exact="Diseases" post="during the COVID-19 EpidemicCirculation202010.1161/CIRCULATIONAHA.120.04701132216640 7.ZhouF.YuT.DuR.FanG.LiuY.LiuZ.XiangJ.WangY.SongB.GuX.et al.Clinical course and risk"/>
  <result pre="EpidemicCirculation202010.1161/CIRCULATIONAHA.120.04701132216640 7.ZhouF.YuT.DuR.FanG.LiuY.LiuZ.XiangJ.WangY.SongB.GuX.et al.Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: A retrospective cohort"/>
  <result pre="novel coronavirus in Wuhan, ChinaLancet (Lond. Engl.)202039549750610.1016/S0140-6736(20)30183-5 9.ShiS.QinM.ShenB.CaiY.LiuT.YangF.GongW.LiuX.LiangJ.ZhaoQ.et al.Association of" exact="Cardiac" post="Injury With Mortality in Hospitalized Patients With COVID-19 in"/>
  <result pre="Wuhan, ChinaJAMA Cardiol.202010.1001/jamacardio.2020.0950 10.ZhuN.ZhangD.WangW.LiX.YangB.SongJ.ZhaoX.HuangB.ShiW.LuR.et al.A Novel Coronavirus from Patients with" exact="Pneumonia" post="in China, 2019New Engl. J. Med.202038272773310.1056/NEJMoa200101731978945 11.SuS.WongG.ShiW.LiuJ.LaiA.C.K.ZhouJ.LiuW.BiY.GaoG.F.Epidemiology, Genetic Recombination,"/>
  <result pre="Patients, Health Care Workers, and Health Systems During the Coronavirus" exact="Disease" post="2019 (COVID-19) PandemicJ. Am. Coll. Cardiol.202010.1016/j.jacc.2020.03.031 13.LuR.ZhaoX.LiJ.NiuP.YangB.WuH.WangW.SongH.HuangB.ZhuN.et al.Genomic characterisation"/>
  <result pre="virus origins and receptor bindingLancet (Lond. Engl.)202039556557410.1016/S0140-6736(20)30251-8 14.collab: Centers for" exact="Disease" post="Control and PreventionInterim U.S. Guidance for Risk Assessment and"/>
  <result pre="Potential Exposure in a Healthcare Setting to Patients with Coronavirus" exact="Disease" post="(COVID-19)Available online: https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-risk-assesment-hcp.html(accessed on 25 April 2020) 15.GeX.Y.LiJ.L.YangX.L.ChmuraA.A.ZhuG.EpsteinJ.H.MazetJ.K.HuB.ZhangW.PengC.et al.Isolation"/>
  <result pre="bat SARS-like coronavirus that uses the ACE2 receptorNature201350353553810.1038/nature1271124172901 16.ZhouP.YangX.L.WangX.G.HuB.ZhangL.ZhangW.SiH.R.ZhuY.LiB.HuangC.L.et al.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
  <result pre="Med.202010.1007/s00134-020-05985-9 19.XuH.ZhongL.DengJ.PengJ.DanH.ZengX.LiT.ChenQ.High expression of ACE2 receptor of 2019-nCoV on the" exact="epithelial" post="cells of oral mucosaInt. J. Oral Sci.202012810.1038/s41368-020-0074-x32094336 20.LiB.YangJ.ZhaoF.ZhiL.WangX.LiuL.BiZ.ZhaoY.Prevalence and"/>
  <result pre="of oral mucosaInt. J. Oral Sci.202012810.1038/s41368-020-0074-x32094336 20.LiB.YangJ.ZhaoF.ZhiL.WangX.LiuL.BiZ.ZhaoY.Prevalence and impact of" exact="cardiovascular" post="metabolic diseases on COVID-19 in ChinaClin. Res. Cardiol. Off."/>
  <result pre="oral mucosaInt. J. Oral Sci.202012810.1038/s41368-020-0074-x32094336 20.LiB.YangJ.ZhaoF.ZhiL.WangX.LiuL.BiZ.ZhaoY.Prevalence and impact of cardiovascular" exact="metabolic diseases" post="on COVID-19 in ChinaClin. Res. Cardiol. Off. J. Ger."/>
  <result pre="21.CoburnB.J.WagnerB.G.BlowerS.Modeling influenza epidemics and pandemics: Insights into the future of" exact="swine flu" post="(H1N1)BMC Med.200973010.1186/1741-7015-7-3019545404 22.ZumlaA.HuiD.S.PerlmanS.Middle East respiratory syndromeLancet (Lond. Engl.)2015386995100710.1016/S0140-6736(15)60454-8 23.PerlmanS.Another"/>
  <result pre="into the future of swine flu (H1N1)BMC Med.200973010.1186/1741-7015-7-3019545404 22.ZumlaA.HuiD.S.PerlmanS.Middle East" exact="respiratory" post="syndromeLancet (Lond. Engl.)2015386995100710.1016/S0140-6736(15)60454-8 23.PerlmanS.Another Decade, Another CoronavirusN. Engl. J."/>
  <result pre="CoronavirusN. Engl. J. Med.202038276076210.1056/NEJMe200112631978944 24.MizumotoK.KagayaK.ZarebskiA.ChowellG.Estimating the asymptomatic proportion of coronavirus" exact="disease" post="2019 (COVID-19) cases on board the Diamond Princess cruise"/>
  <result pre="the Diamond Princess cruise ship, Yokohama, Japan, 2020Eurosurveillance202025200018010.2807/1560-7917.ES.2020.25.10.200018032183930 25.ZouL.RuanF.HuangM.LiangL.HuangH.HongZ.YuJ.KangM.SongY.XiaJ.et al.SARS-CoV-2" exact="Viral" post="Load in Upper Respiratory Specimens of Infected PatientsN. Engl."/>
  <result pre="ship, Yokohama, Japan, 2020Eurosurveillance202025200018010.2807/1560-7917.ES.2020.25.10.200018032183930 25.ZouL.RuanF.HuangM.LiangL.HuangH.HongZ.YuJ.KangM.SongY.XiaJ.et al.SARS-CoV-2 Viral Load in Upper" exact="Respiratory" post="Specimens of Infected PatientsN. Engl. J. Med.20203821177117910.1056/NEJMc200173732074444 26.PeirisJ.S.ChuC.M.ChengV.C.ChanK.S.HungI.F.PoonL.L.LawK.I.TangB.S.HonT.Y.ChanC.S.et al.Clinical"/>
  <result pre="of Infected PatientsN. Engl. J. Med.20203821177117910.1056/NEJMc200173732074444 26.PeirisJ.S.ChuC.M.ChengV.C.ChanK.S.HungI.F.PoonL.L.LawK.I.TangB.S.HonT.Y.ChanC.S.et al.Clinical progression and" exact="viral" post="load in a community outbreak of coronavirus-associated SARS pneumonia:"/>
  <result pre="A prospective studyLancet (Lond. Engl.)20033611767177210.1016/S0140-6736(03)13412-5 27.GuanW.J.NiZ.Y.HuY.LiangW.H.OuC.Q.HeJ.X.LiuL.ShanH.LeiC.L.HuiD.S.C.et al.Clinical Characteristics of Coronavirus" exact="Disease" post="2019 in ChinaN. Engl. J. Med.20203821708172010.1056/NEJMoa200203232109013 28.LauerS.A.GrantzK.H.BiQ.JonesF.K.ZhengQ.MeredithH.R.AzmanA.S.ReichN.G.LesslerJ.The Incubation Period"/>
  <result pre="in ChinaN. Engl. J. Med.20203821708172010.1056/NEJMoa200203232109013 28.LauerS.A.GrantzK.H.BiQ.JonesF.K.ZhengQ.MeredithH.R.AzmanA.S.ReichN.G.LesslerJ.The Incubation Period of Coronavirus" exact="Disease" post="2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and"/>
  <result pre="J. Med.202010.1056/NEJMc2009020 32.WuZ.McGooganJ.M.Characteristics of and Important Lessons From the Coronavirus" exact="Disease" post="2019 (COVID-19) Outbreak in China: Summary of a Report"/>
  <result pre="a Report of 72314 Cases From the Chinese Center for" exact="Disease" post="Control and PreventionJAMA202010.1001/jama.2020.2648 33.OnderG.RezzaG.BrusaferroS.Case-Fatality Rate and Characteristics of Patients"/>
  <result pre="with hospitalization and critical illness among 4,103 patients with COVID-19" exact="disease" post="in New York CitymedRxiv202010.1101/2020.04.08.20057794 36.SattarN.McInnesI.B.McMurrayJ.J.V.Obesity a Risk Factor for"/>
  <result pre="disease in New York CitymedRxiv202010.1101/2020.04.08.20057794 36.SattarN.McInnesI.B.McMurrayJ.J.V.Obesity a Risk Factor for" exact="Severe" post="COVID-19 Infection: Multiple Potential MechanismsCirculation202010.1161/CIRCULATIONAHA.120.047659 37.MatthayM.A.AldrichJ.M.GottsJ.E.Treatment for severe acute"/>
  <result pre="York CitymedRxiv202010.1101/2020.04.08.20057794 36.SattarN.McInnesI.B.McMurrayJ.J.V.Obesity a Risk Factor for Severe COVID-19 Infection:" exact="Multiple" post="Potential MechanismsCirculation202010.1161/CIRCULATIONAHA.120.047659 37.MatthayM.A.AldrichJ.M.GottsJ.E.Treatment for severe acute respiratory distress syndrome"/>
  <result pre="for Severe COVID-19 Infection: Multiple Potential MechanismsCirculation202010.1161/CIRCULATIONAHA.120.047659 37.MatthayM.A.AldrichJ.M.GottsJ.E.Treatment for severe" exact="acute" post="respiratory distress syndrome from COVID-19Lancet Respir. Med.202010.1016/S2213-2600(20)30127-2 38.KalilA.C.Treating COVID-19-Off-Label"/>
  <result pre="Severe COVID-19 Infection: Multiple Potential MechanismsCirculation202010.1161/CIRCULATIONAHA.120.047659 37.MatthayM.A.AldrichJ.M.GottsJ.E.Treatment for severe acute" exact="respiratory" post="distress syndrome from COVID-19Lancet Respir. Med.202010.1016/S2213-2600(20)30127-2 38.KalilA.C.Treating COVID-19-Off-Label Drug"/>
  <result pre="Infection: Multiple Potential MechanismsCirculation202010.1161/CIRCULATIONAHA.120.047659 37.MatthayM.A.AldrichJ.M.GottsJ.E.Treatment for severe acute respiratory distress" exact="syndrome" post="from COVID-19Lancet Respir. Med.202010.1016/S2213-2600(20)30127-2 38.KalilA.C.Treating COVID-19-Off-Label Drug Use, Compassionate"/>
  <result pre="ARDS during the COVID-19 pandemic and other outbreaks of emerging" exact="infectious" post="diseasesLancet Respir. Med.202010.1016/S2213-2600(20)30121-1 40.BoothC.M.MatukasL.M.TomlinsonG.A.RachlisA.R.RoseD.B.DwoshH.A.WalmsleyS.L.MazzulliT.AvendanoM.DerkachP.et al.Clinical features and short-term outcomes"/>
  <result pre="greater Toronto areaJAMA20032892801280910.1001/jama.289.21.JOC3088512734147 41.BadawiA.RyooS.G.Prevalence of comorbidities in the Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV): A systematic review and meta-analysisInt. J."/>
  <result pre="Toronto areaJAMA20032892801280910.1001/jama.289.21.JOC3088512734147 41.BadawiA.RyooS.G.Prevalence of comorbidities in the Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV): A systematic review and meta-analysisInt. J. Infect."/>
  <result pre="Dis.20164912913310.1016/j.ijid.2016.06.015 42.GuoT.FanY.ChenM.WuX.ZhangL.HeT.WangH.WanJ.WangX.LuZ.Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus" exact="Disease" post="2019 (COVID-19)JAMA Cardiol.202010.1001/jamacardio.2020.1017 43.RuanQ.YangK.WangW.JiangL.SongJ.Clinical predictors of mortality due to"/>
  <result pre="of 150 patients from Wuhan, ChinaIntensiv. Care Med.202010.1007/s00134-020-05991-x32125452 44.ClerkinK.J.FriedJ.A.RaikhelkarJ.SayerG.GriffinJ.M.MasoumiA.JainS.S.BurkhoffD.KumaraiahD.RabbaniL.et al.Coronavirus" exact="Disease" post="2019 (COVID-19) and Cardiovascular DiseaseCirculation202010.1161/CIRCULATIONAHA.120.046941 45.WeyandC.M.GoronzyJ.J.Aging of the Immune"/>
  <result pre="Mechanisms and Therapeutic TargetsAnn. Am. Thorac. Soc.201613Suppl. 542242810.1513/AnnalsATS.201602-095AW 46.DooleyK.E.ChaissonR.E.Tuberculosis and" exact="diabetes" post="mellitus: Convergence of two epidemicsLancet Infect. Dis.2009973774610.1016/S1473-3099(09)70282-819926034 47.RodriguesB.S.DavidC.CostaJ.FerreiraJ.J.PintoF.J.CaldeiraD.Influenza vaccination"/>
  <result pre="of two epidemicsLancet Infect. Dis.2009973774610.1016/S1473-3099(09)70282-819926034 47.RodriguesB.S.DavidC.CostaJ.FerreiraJ.J.PintoF.J.CaldeiraD.Influenza vaccination in patients with" exact="heart" post="failure: A systematic review and meta-analysis of observational studiesHeart"/>
  <result pre="of observational studiesHeart (Br. Card. Soc.)202010635035710.1136/heartjnl-2019-31519331444266 48.CaldeiraD.RodriguesB.DavidC.CostaJ.PintoF.J.FerreiraJ.J.The association of influenza" exact="infection" post="and vaccine with myocardial infarction: Systematic review and meta-analysis"/>
  <result pre="May 2020) 52.InciardiR.M.LupiL.ZacconeG.ItaliaL.RaffoM.TomasoniD.CaniD.S.CeriniM.FarinaD.GavazziE.et al.Cardiac Involvement in a Patient With Coronavirus" exact="Disease" post="2019 (COVID-19)JAMA Cardiol.202010.1001/jamacardio.2020.1096 53.OuditG.Y.KassiriZ.JiangC.LiuP.P.PoutanenS.M.PenningerJ.M.ButanyJ.SARS-coronavirus modulation of myocardial ACE2 expression"/>
  <result pre="and inflammation in patients with SARSEur. J. Clin. Investig.20093961862510.1111/j.1365-2362.2009.02153.x19453650 54.AlhogbaniT.Acute" exact="myocarditis" post="associated with novel Middle east respiratory syndrome coronavirusAnn. Saudi"/>
  <result pre="J. Clin. Investig.20093961862510.1111/j.1365-2362.2009.02153.x19453650 54.AlhogbaniT.Acute myocarditis associated with novel Middle east" exact="respiratory" post="syndrome coronavirusAnn. Saudi Med.201636788010.5144/0256-4947.2016.7826922692 55.HuiH.ZhangY.YangX.WangX.HeB.LiL.LiH.TianJ.ChenY.Clinical and radiographic features of"/>
  <result pre="Clin. Investig.20093961862510.1111/j.1365-2362.2009.02153.x19453650 54.AlhogbaniT.Acute myocarditis associated with novel Middle east respiratory" exact="syndrome" post="coronavirusAnn. Saudi Med.201636788010.5144/0256-4947.2016.7826922692 55.HuiH.ZhangY.YangX.WangX.HeB.LiL.LiH.TianJ.ChenY.Clinical and radiographic features of cardiac"/>
  <result pre="in patients with 2019 novel coronavirus pneumoniamedRxiv202010.1101/2020.02.24.20027052 56.XiongT.Y.RedwoodS.PrendergastB.ChenM.Coronaviruses and the" exact="cardiovascular" post="system: Acute and long-term implicationsEur. Heart J.202010.1093/eurheartj/ehaa231 57.TavazziG.PellegriniC.MaurelliM.BelliatoM.SciuttiF.BottazziA.SepeP.A.ResascoT.CamporotondoR.BrunoR.et al.Myocardial"/>
  <result pre="with 2019 novel coronavirus pneumoniamedRxiv202010.1101/2020.02.24.20027052 56.XiongT.Y.RedwoodS.PrendergastB.ChenM.Coronaviruses and the cardiovascular system:" exact="Acute" post="and long-term implicationsEur. Heart J.202010.1093/eurheartj/ehaa231 57.TavazziG.PellegriniC.MaurelliM.BelliatoM.SciuttiF.BottazziA.SepeP.A.ResascoT.CamporotondoR.BrunoR.et al.Myocardial localization of"/>
  <result pre="pneumoniamedRxiv202010.1101/2020.02.24.20027052 56.XiongT.Y.RedwoodS.PrendergastB.ChenM.Coronaviruses and the cardiovascular system: Acute and long-term implicationsEur." exact="Heart" post="J.202010.1093/eurheartj/ehaa231 57.TavazziG.PellegriniC.MaurelliM.BelliatoM.SciuttiF.BottazziA.SepeP.A.ResascoT.CamporotondoR.BrunoR.et al.Myocardial localization of coronavirus in COVID-19 cardiogenic"/>
  <result pre="57.TavazziG.PellegriniC.MaurelliM.BelliatoM.SciuttiF.BottazziA.SepeP.A.ResascoT.CamporotondoR.BrunoR.et al.Myocardial localization of coronavirus in COVID-19 cardiogenic shockEur. J." exact="Heart" post="Fail.202010.1002/ejhf.1828 58.MeyerP.DegrauweS.DeldenC.V.GhadriJ.-R.TemplinC.Typical takotsubo syndrome triggered by SARS-CoV-2 infectionEur. Heart"/>
  <result pre="coronavirus in COVID-19 cardiogenic shockEur. J. Heart Fail.202010.1002/ejhf.1828 58.MeyerP.DegrauweS.DeldenC.V.GhadriJ.-R.TemplinC.Typical takotsubo" exact="syndrome" post="triggered by SARS-CoV-2 infectionEur. Heart J.202010.1093/eurheartj/ehaa306 59.HuH.MaF.WeiX.FangY.Coronavirus fulminant myocarditis"/>
  <result pre="J. Heart Fail.202010.1002/ejhf.1828 58.MeyerP.DegrauweS.DeldenC.V.GhadriJ.-R.TemplinC.Typical takotsubo syndrome triggered by SARS-CoV-2 infectionEur." exact="Heart" post="J.202010.1093/eurheartj/ehaa306 59.HuH.MaF.WeiX.FangY.Coronavirus fulminant myocarditis saved with glucocorticoid and human"/>
  <result pre="takotsubo syndrome triggered by SARS-CoV-2 infectionEur. Heart J.202010.1093/eurheartj/ehaa306 59.HuH.MaF.WeiX.FangY.Coronavirus fulminant" exact="myocarditis" post="saved with glucocorticoid and human immunoglobulinEur. Heart J.202010.1093/eurheartj/ehaa190 60.ZengJ.H.LiuY.X.YuanJ.WangF.X.WuW.B.LiJ.X.WangL.F.GaoH.WangY.DongC.F.et"/>
  <result pre="J.202010.1093/eurheartj/ehaa306 59.HuH.MaF.WeiX.FangY.Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulinEur." exact="Heart" post="J.202010.1093/eurheartj/ehaa190 60.ZengJ.H.LiuY.X.YuanJ.WangF.X.WuW.B.LiJ.X.WangL.F.GaoH.WangY.DongC.F.et al.First Case of COVID-19 Infection with Fulminant"/>
  <result pre="and human immunoglobulinEur. Heart J.202010.1093/eurheartj/ehaa190 60.ZengJ.H.LiuY.X.YuanJ.WangF.X.WuW.B.LiJ.X.WangL.F.GaoH.WangY.DongC.F.et al.First Case of COVID-19" exact="Infection" post="with Fulminant Myocarditis Complication: Case Report and InsightsPreprints202010.20944/preprints202003.0180.v1 61.KwongJ.C.SchwartzK.L.CampitelliM.A.ChungH.CrowcroftN.S.KarnauchowT.KatzK.KoD.T.McGeerA.J.McNallyD.et"/>
  <result pre="Fulminant Myocarditis Complication: Case Report and InsightsPreprints202010.20944/preprints202003.0180.v1 61.KwongJ.C.SchwartzK.L.CampitelliM.A.ChungH.CrowcroftN.S.KarnauchowT.KatzK.KoD.T.McGeerA.J.McNallyD.et al.Acute Myocardial" exact="Infarction" post="after Laboratory-Confirmed Influenza InfectionN. Engl. J. Med.201837834535310.1056/NEJMoa170209029365305 62.ThygesenK.AlpertJ.S.JaffeA.S.ChaitmanB.R.BaxJ.J.MorrowD.A.WhiteH.D.Fourth Universal"/>
  <result pre="Influenza InfectionN. Engl. J. Med.201837834535310.1056/NEJMoa170209029365305 62.ThygesenK.AlpertJ.S.JaffeA.S.ChaitmanB.R.BaxJ.J.MorrowD.A.WhiteH.D.Fourth Universal Definition of Myocardial" exact="Infarction" post="(2018)J. Am. Coll. Cardiol.2018722231226410.1016/j.jacc.2018.08.103830153967 63.HendrenN.S.DraznerM.H.BozkurtB.LeslieT.CooperJ.Description and Proposed Management of"/>
  <result pre="(2018)J. Am. Coll. Cardiol.2018722231226410.1016/j.jacc.2018.08.103830153967 63.HendrenN.S.DraznerM.H.BozkurtB.LeslieT.CooperJ.Description and Proposed Management of the" exact="Acute" post="COVID-19 Cardiovascular SyndromeCirculation202010.1161/CIRCULATIONAHA.120.04734932297796 64.collab: American College of CardiologyTroponin and"/>
  <result pre="and Proposed Management of the Acute COVID-19 Cardiovascular SyndromeCirculation202010.1161/CIRCULATIONAHA.120.04734932297796 64.collab:" exact="American" post="College of CardiologyTroponin and BNP Use in COVID-19Available online:"/>
  <result pre="Use in COVID-19Available online: https://www.acc.org/latest-in-cardiology/articles/2020/03/18/15/25/troponinand-bnp-use-in-covid19(accessed on 25 April 2020) 65.KimI.C.KimJ.Y.KimH.A.HanS.COVID-19-related" exact="myocarditis" post="in a 21-year-old female patientEur. Heart J.202010.1093/eurheartj/ehaa28832282027 66.collab: World"/>
  <result pre="https://www.acc.org/latest-in-cardiology/articles/2020/03/18/15/25/troponinand-bnp-use-in-covid19(accessed on 25 April 2020) 65.KimI.C.KimJ.Y.KimH.A.HanS.COVID-19-related myocarditis in a 21-year-old" exact="female" post="patientEur. Heart J.202010.1093/eurheartj/ehaa28832282027 66.collab: World Health OrganizationClinical Management of"/>
  <result pre="25 April 2020) 65.KimI.C.KimJ.Y.KimH.A.HanS.COVID-19-related myocarditis in a 21-year-old female patientEur." exact="Heart" post="J.202010.1093/eurheartj/ehaa28832282027 66.collab: World Health OrganizationClinical Management of Severe Acute"/>
  <result pre="female patientEur. Heart J.202010.1093/eurheartj/ehaa28832282027 66.collab: World Health OrganizationClinical Management of" exact="Severe" post="Acute Respiratory Infection When COVID-19 is SuspectedAvailable online: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected(accessed"/>
  <result pre="patientEur. Heart J.202010.1093/eurheartj/ehaa28832282027 66.collab: World Health OrganizationClinical Management of Severe" exact="Acute" post="Respiratory Infection When COVID-19 is SuspectedAvailable online: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected(accessed on"/>
  <result pre="Heart J.202010.1093/eurheartj/ehaa28832282027 66.collab: World Health OrganizationClinical Management of Severe Acute" exact="Respiratory" post="Infection When COVID-19 is SuspectedAvailable online: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected(accessed on 25"/>
  <result pre="J.202010.1093/eurheartj/ehaa28832282027 66.collab: World Health OrganizationClinical Management of Severe Acute Respiratory" exact="Infection" post="When COVID-19 is SuspectedAvailable online: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected(accessed on 25 April"/>
  <result pre="2020) 67.AlshahraniM.S.SindiA.AlshamsiF.Al-OmariA.El TahanM.AlahmadiB.ZeinA.KhataniN.Al-HameedF.AlamriS.et al.Extracorporeal membrane oxygenation for severe Middle East" exact="respiratory" post="syndrome coronavirusAnn. Intensiv. Care20188310.1186/s13613-017-0350-x 68.MadjidM.ConnollyA.T.NabutovskyY.Safavi-NaeiniP.RazaviM.MillerC.C.Effect of High Influenza Activity"/>
  <result pre="67.AlshahraniM.S.SindiA.AlshamsiF.Al-OmariA.El TahanM.AlahmadiB.ZeinA.KhataniN.Al-HameedF.AlamriS.et al.Extracorporeal membrane oxygenation for severe Middle East respiratory" exact="syndrome" post="coronavirusAnn. Intensiv. Care20188310.1186/s13613-017-0350-x 68.MadjidM.ConnollyA.T.NabutovskyY.Safavi-NaeiniP.RazaviM.MillerC.C.Effect of High Influenza Activity on"/>
  <result pre="Intensiv. Care20188310.1186/s13613-017-0350-x 68.MadjidM.ConnollyA.T.NabutovskyY.Safavi-NaeiniP.RazaviM.MillerC.C.Effect of High Influenza Activity on Risk of" exact="Ventricular" post="Arrhythmias Requiring Therapy in Patients With Implantable Cardiac Defibrillators"/>
  <result pre="Care20188310.1186/s13613-017-0350-x 68.MadjidM.ConnollyA.T.NabutovskyY.Safavi-NaeiniP.RazaviM.MillerC.C.Effect of High Influenza Activity on Risk of Ventricular" exact="Arrhythmias" post="Requiring Therapy in Patients With Implantable Cardiac Defibrillators and"/>
  <result pre="Risk of Ventricular Arrhythmias Requiring Therapy in Patients With Implantable" exact="Cardiac" post="Defibrillators and Cardiac Resynchronization Therapy DefibrillatorsAm. J. Cardiol.2019124445010.1016/j.amjcard.2019.04.01131047651 69.YuC.M.WongR.S.WuE.B.KongS.L.WongJ.YipG.W.SooY.O.ChiuM.L.ChanY.S.HuiD.et"/>
  <result pre="Arrhythmias Requiring Therapy in Patients With Implantable Cardiac Defibrillators and" exact="Cardiac" post="Resynchronization Therapy DefibrillatorsAm. J. Cardiol.2019124445010.1016/j.amjcard.2019.04.01131047651 69.YuC.M.WongR.S.WuE.B.KongS.L.WongJ.YipG.W.SooY.O.ChiuM.L.ChanY.S.HuiD.et al.Cardiovascular complications of"/>
  <result pre="Resynchronization Therapy DefibrillatorsAm. J. Cardiol.2019124445010.1016/j.amjcard.2019.04.01131047651 69.YuC.M.WongR.S.WuE.B.KongS.L.WongJ.YipG.W.SooY.O.ChiuM.L.ChanY.S.HuiD.et al.Cardiovascular complications of severe" exact="acute" post="respiratory syndromePostgrad. Med. J.20068214014410.1136/pgmj.2005.03751516461478 70.TangN.LiD.WangX.SunZ.Abnormal coagulation parameters are associated"/>
  <result pre="Therapy DefibrillatorsAm. J. Cardiol.2019124445010.1016/j.amjcard.2019.04.01131047651 69.YuC.M.WongR.S.WuE.B.KongS.L.WongJ.YipG.W.SooY.O.ChiuM.L.ChanY.S.HuiD.et al.Cardiovascular complications of severe acute" exact="respiratory" post="syndromePostgrad. Med. J.20068214014410.1136/pgmj.2005.03751516461478 70.TangN.LiD.WangX.SunZ.Abnormal coagulation parameters are associated with"/>
  <result pre="Thromb. Haemost.20201884484710.1111/jth.1476832073213 71.ThachilJ.TangN.GandoS.FalangaA.CattaneoM.LeviM.ClarkC.IbaT.ISTH interim guidance on recognition and management of" exact="coagulopathy" post="in COVID-19J. Thromb. Haemost.202010.1111/jth.1481032338827 72.ChongP.Y.ChuiP.LingA.E.FranksT.J.TaiD.Y.LeoY.S.KawG.J.WansaicheongG.ChanK.P.Ean OonL.L.et al.Analysis of deaths"/>
  <result pre="Thromb. Haemost.202010.1111/jth.1481032338827 72.ChongP.Y.ChuiP.LingA.E.FranksT.J.TaiD.Y.LeoY.S.KawG.J.WansaicheongG.ChanK.P.Ean OonL.L.et al.Analysis of deaths during the severe" exact="acute" post="respiratory syndrome (SARS) epidemic in Singapore: Challenges in determining"/>
  <result pre="Haemost.202010.1111/jth.1481032338827 72.ChongP.Y.ChuiP.LingA.E.FranksT.J.TaiD.Y.LeoY.S.KawG.J.WansaicheongG.ChanK.P.Ean OonL.L.et al.Analysis of deaths during the severe acute" exact="respiratory" post="syndrome (SARS) epidemic in Singapore: Challenges in determining a"/>
  <result pre="72.ChongP.Y.ChuiP.LingA.E.FranksT.J.TaiD.Y.LeoY.S.KawG.J.WansaicheongG.ChanK.P.Ean OonL.L.et al.Analysis of deaths during the severe acute respiratory" exact="syndrome" post="(SARS) epidemic in Singapore: Challenges in determining a SARS"/>
  <result pre="SARS diagnosisArch. Pathol. Lab. Med.200412819520410.1043/1543-2165(2004)1282.0.co;214736283 73.ZhangL.ZhuF.XieL.WangC.WangJ.ChenR.JiaP.GuanH.Q.PengL.ChenY.et al.Clinical characteristics of COVID-19-infected" exact="cancer" post="patients: A retrospective case study in three hospitals within"/>
  <result pre="case study in three hospitals within Wuhan, ChinaAnn. Oncol.202010.1016/j.annonc.2020.03.296 74.DanziG.B.LoffiM.GaleazziG.GherbesiE.Acute" exact="pulmonary embolism" post="and COVID-19 pneumonia: A random association?Eur. Heart J.202010.1093/eurheartj/ehaa254 75.XieY.WangX.YangP.ZhangS.COVID-19"/>
  <result pre="Oncol.202010.1016/j.annonc.2020.03.296 74.DanziG.B.LoffiM.GaleazziG.GherbesiE.Acute pulmonary embolism and COVID-19 pneumonia: A random association?Eur." exact="Heart" post="J.202010.1093/eurheartj/ehaa254 75.XieY.WangX.YangP.ZhangS.COVID-19 Complicated by Acute Pulmonary EmbolismRadiol. Cardiothorac. Imaging20202e20006710.1148/ryct.2020200067"/>
  <result pre="embolism and COVID-19 pneumonia: A random association?Eur. Heart J.202010.1093/eurheartj/ehaa254 75.XieY.WangX.YangP.ZhangS.COVID-19" exact="Complicated" post="by Acute Pulmonary EmbolismRadiol. Cardiothorac. Imaging20202e20006710.1148/ryct.2020200067 76.AiT.YangZ.HouH.ZhanC.ChenC.LvW.TaoQ.SunZ.XiaL.Correlation of Chest"/>
  <result pre="COVID-19 pneumonia: A random association?Eur. Heart J.202010.1093/eurheartj/ehaa254 75.XieY.WangX.YangP.ZhangS.COVID-19 Complicated by" exact="Acute" post="Pulmonary EmbolismRadiol. Cardiothorac. Imaging20202e20006710.1148/ryct.2020200067 76.AiT.YangZ.HouH.ZhanC.ChenC.LvW.TaoQ.SunZ.XiaL.Correlation of Chest CT and"/>
  <result pre="pneumonia: A random association?Eur. Heart J.202010.1093/eurheartj/ehaa254 75.XieY.WangX.YangP.ZhangS.COVID-19 Complicated by Acute" exact="Pulmonary" post="EmbolismRadiol. Cardiothorac. Imaging20202e20006710.1148/ryct.2020200067 76.AiT.YangZ.HouH.ZhanC.ChenC.LvW.TaoQ.SunZ.XiaL.Correlation of Chest CT and RT-PCR"/>
  <result pre="Imaging20202e20006710.1148/ryct.2020200067 76.AiT.YangZ.HouH.ZhanC.ChenC.LvW.TaoQ.SunZ.XiaL.Correlation of Chest CT and RT-PCR Testing in Coronavirus" exact="Disease" post="2019 (COVID-19) in China: A Report of 1014 CasesRadiology202010.1148/radiol.202020064232101510"/>
  <result pre="Report of 1014 CasesRadiology202010.1148/radiol.202020064232101510 77.YangY.YangM.ShenC.WangF.YuanJ.LiJ.ZhangM.WangZ.XingL.WeiJ.et al.Evaluating the accuracy of different" exact="respiratory" post="specimens in the laboratory diagnosis and monitoring the viral"/>
  <result pre="different respiratory specimens in the laboratory diagnosis and monitoring the" exact="viral" post="shedding of 2019-nCoV infectionsmedRxiv202010.1101/2020.02.11.20021493 78.AlosaimiB.HamedM.E.NaeemA.AlsharefA.A.AlQahtaniS.Y.AlDosariK.M.AlamriA.A.Al-EisaK.KhojahT.AssiriA.M.et al.MERS-CoV infection is associated"/>
  <result pre="and monitoring the viral shedding of 2019-nCoV infectionsmedRxiv202010.1101/2020.02.11.20021493 78.AlosaimiB.HamedM.E.NaeemA.AlsharefA.A.AlQahtaniS.Y.AlDosariK.M.AlamriA.A.Al-EisaK.KhojahT.AssiriA.M.et al.MERS-CoV" exact="infection" post="is associated with downregulation of genes encoding Th1 and"/>
  <result pre="Th2 cytokines/chemokines and elevated inflammatory innate immune response in the" exact="lower" post="respiratory tractCytokine202012615489510.1016/j.cyto.2019.15489531706200 79.LinL.LuL.CaoW.LiT.Hypothesis for potential pathogenesis of SARS-CoV-2 infectionâ€&quot;a"/>
  <result pre="cytokines/chemokines and elevated inflammatory innate immune response in the lower" exact="respiratory" post="tractCytokine202012615489510.1016/j.cyto.2019.15489531706200 79.LinL.LuL.CaoW.LiT.Hypothesis for potential pathogenesis of SARS-CoV-2 infectionâ€&quot;a review"/>
  <result pre="of SARS-CoV-2 infectionâ€&quot;a review of immune changes in patients with" exact="viral" post="pneumoniaEmerg. Microbes Infect.2020972773210.1080/22221751.2020.174619932196410 80.EscherR.BreakeyN.LÃ¤mmleB.Severe COVID-19 infection associated with endothelial"/>
  <result pre="changes in patients with viral pneumoniaEmerg. Microbes Infect.2020972773210.1080/22221751.2020.174619932196410 80.EscherR.BreakeyN.LÃ¤mmleB.Severe COVID-19" exact="infection" post="associated with endothelial activationThromb. Res.202010.1016/j.thromres.2020.04.014 81.SarduC.GambardellaJ.MorelliM.B.WangX.MarfellaR.SantulliG.Is COVID-19 an Endothelial"/>
  <result pre="COVID-19 an Endothelial Disease? Clinical and Basic EvidencePreprints202010.20944/preprints202004.0204.v1 82.VargaZ.FlammerA.J.SteigerP.HabereckerM.AndermattR.ZinkernagelA.S.MehraM.R.SchuepbachR.A.RuschitzkaF.MochH.Endothelial cell" exact="infection" post="and endotheliitis in COVID-19Lancet (Lond. Engl.)202010.1016/S0140-6736(20)30937-5 83.SantosA.R.FreitasP.FerreiraJ.OliveiraA.GoncalvesM.FariaD.Bicho AugustoJ.SimoesJ.SantosA.GagoM.et al.Risk"/>
  <result pre="in COVID-19Lancet (Lond. Engl.)202010.1016/S0140-6736(20)30937-5 83.SantosA.R.FreitasP.FerreiraJ.OliveiraA.GoncalvesM.FariaD.Bicho AugustoJ.SimoesJ.SantosA.GagoM.et al.Risk stratification in normotensive" exact="acute" post="pulmonary embolism patients: Focus on the intermediate-high risk subgroupEur."/>
  <result pre="COVID-19Lancet (Lond. Engl.)202010.1016/S0140-6736(20)30937-5 83.SantosA.R.FreitasP.FerreiraJ.OliveiraA.GoncalvesM.FariaD.Bicho AugustoJ.SimoesJ.SantosA.GagoM.et al.Risk stratification in normotensive acute" exact="pulmonary embolism" post="patients: Focus on the intermediate-high risk subgroupEur. Heart J."/>
  <result pre="acute pulmonary embolism patients: Focus on the intermediate-high risk subgroupEur." exact="Heart" post="J. Acute Cardiovasc. Care201910.1177/2048872619846506 84.KosugeM.EbinaT.HibiK.TsukaharaK.IwahashiN.UmemuraS.KimuraK.Differences in negative T waves"/>
  <result pre="embolism patients: Focus on the intermediate-high risk subgroupEur. Heart J." exact="Acute" post="Cardiovasc. Care201910.1177/2048872619846506 84.KosugeM.EbinaT.HibiK.TsukaharaK.IwahashiN.UmemuraS.KimuraK.Differences in negative T waves between acute"/>
  <result pre="J. Acute Cardiovasc. Care201910.1177/2048872619846506 84.KosugeM.EbinaT.HibiK.TsukaharaK.IwahashiN.UmemuraS.KimuraK.Differences in negative T waves between" exact="acute" post="pulmonary embolism and acute coronary syndromeCirc. J. Off. J."/>
  <result pre="Acute Cardiovasc. Care201910.1177/2048872619846506 84.KosugeM.EbinaT.HibiK.TsukaharaK.IwahashiN.UmemuraS.KimuraK.Differences in negative T waves between acute" exact="pulmonary embolism" post="and acute coronary syndromeCirc. J. Off. J. Jpn. Circ."/>
  <result pre="84.KosugeM.EbinaT.HibiK.TsukaharaK.IwahashiN.UmemuraS.KimuraK.Differences in negative T waves between acute pulmonary embolism and" exact="acute" post="coronary syndromeCirc. J. Off. J. Jpn. Circ. Soc.20147848348910.1253/circj.CJ-13-1064 85.HammingI.TimensW.BulthuisM.L.LelyA.T.NavisG.van"/>
  <result pre="SARS pathogenesisJ. Pathol.200420363163710.1002/path.157015141377 86.ImaiY.KubaK.RaoS.HuanY.GuoF.GuanB.YangP.SaraoR.WadaT.Leong-PoiH.et al.Angiotensin-converting enzyme 2 protects from severe" exact="acute" post="lung failureNature200543611211610.1038/nature0371216001071 87.PatelA.B.VermaA.COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin"/>
  <result pre="of the renin-angiotensin system be withdrawn in patients with COVID-19?Eur." exact="Heart" post="J.202010.1093/eurheartj/ehaa235 89.KassiriZ.ZhongJ.GuoD.BasuR.WangX.LiuP.P.ScholeyJ.W.PenningerJ.M.OuditG.Y.Loss of angiotensin-converting enzyme 2 accelerates maladaptive left"/>
  <result pre="accelerates maladaptive left ventricular remodeling in response to myocardial infarctionCirc." exact="Heart" post="Fail.2009244645510.1161/CIRCHEARTFAILURE.108.84012419808375 90.VaduganathanM.VardenyO.MichelT.McMurrayJ.J.V.PfefferM.A.SolomonS.D.Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19N. Engl."/>
  <result pre="in Patients with Covid-19N. Engl. J. Med.202010.1056/NEJMsr2005760 91.FangL.KarakiulakisG.RothM.Are patients with" exact="hypertension" post="and diabetes mellitus at increased risk for COVID-19 infection?Lancet"/>
  <result pre="with Covid-19N. Engl. J. Med.202010.1056/NEJMsr2005760 91.FangL.KarakiulakisG.RothM.Are patients with hypertension and" exact="diabetes mellitus" post="at increased risk for COVID-19 infection?Lancet Respir. Med.202010.1016/S2213-2600(20)30116-8 92.ZhengY.Y.MaY.T.ZhangJ.Y.XieX.COVID-19"/>
  <result pre="increased risk for COVID-19 infection?Lancet Respir. Med.202010.1016/S2213-2600(20)30116-8 92.ZhengY.Y.MaY.T.ZhangJ.Y.XieX.COVID-19 and the" exact="cardiovascular" post="systemNat. Rev. Cardiol.20201725926010.1038/s41569-020-0360-532139904 93.FerrarioC.M.JessupJ.ChappellM.C.AverillD.B.BrosnihanK.B.TallantE.A.DizD.I.GallagherP.E.Effect of angiotensin-converting enzyme inhibition and"/>
  <result pre="cardiac angiotensin-converting enzyme 2Circulation20051112605261010.1161/CIRCULATIONAHA.104.51046115897343 94.IshiyamaY.GallagherP.E.AverillD.B.TallantE.A.BrosnihanK.B.FerrarioC.M.Upregulation of angiotensin-converting enzyme 2 after" exact="myocardial infarction" post="by blockade of angiotensin II receptorsHypertension (Dallas Tex. 1979)20044397097610.1161/01.HYP.0000124667.34652.1a"/>
  <result pre="coronary artery diseasePLoS ONE201813e019814410.1371/journal.pone.019814429897923 97.EpelmanS.ShresthaK.TroughtonR.W.FrancisG.S.SenS.KleinA.L.TangW.H.Soluble angiotensin-converting enzyme 2 in human" exact="heart" post="failure: Relation with myocardial function and clinical outcomesJ. Card."/>
  <result pre="and Angiotensin II Receptor Blockers with Mortality Among Patients With" exact="Hypertension" post="Hospitalized With COVID-19Circ. Res.202010.1161/CIRCRESAHA.120.317134 99.collab: American College of CardiologyHFSA/ACC/AHA"/>
  <result pre="Mortality Among Patients With Hypertension Hospitalized With COVID-19Circ. Res.202010.1161/CIRCRESAHA.120.317134 99.collab:" exact="American" post="College of CardiologyHFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS"/>
  <result pre="European Society of CardiologyPosition Statement of the ESC Council on" exact="Hypertension" post="on ACE-Inhibitors and Angiotensin Receptor BlockersAvailable online: https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang(accessed on"/>
  <result pre="Cardiovascular SocietyCOVID-19 and Concerns Regarding Use of ACEi/ARB/ARNi Medications for" exact="Heart Failure" post="or HypertensionAvailable online: http://www.ccs.ca/images/Images_2020/CCS_CHFS_statement_regarding_COVID_EN.pdf(accessed on 25 April 2020) 102.MadjidM.Safavi-NaeiniP.SolomonS.D.VardenyO.Potential"/>
  <result pre="SocietyCOVID-19 and Concerns Regarding Use of ACEi/ARB/ARNi Medications for Heart" exact="Failure" post="or HypertensionAvailable online: http://www.ccs.ca/images/Images_2020/CCS_CHFS_statement_regarding_COVID_EN.pdf(accessed on 25 April 2020) 102.MadjidM.Safavi-NaeiniP.SolomonS.D.VardenyO.Potential"/>
  <result pre="Cardiol.202010.1001/jamacardio.2020.128632219363 103.CaoB.WangY.WenD.LiuW.WangJ.FanG.RuanL.SongB.CaiY.WeiM.et al.A Trial of Lopinavir-Ritonavir in Adults Hospitalized with" exact="Severe" post="Covid-19N. Engl. J. Med.20203821787179910.1056/NEJMoa200128232187464 104.WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and chloroquine effectively inhibit"/>
  <result pre="on 25 April 2020) 107.YogasundaramH.HungW.PatersonI.D.SergiC.OuditG.Y.Chloroquine-induced cardiomyopathy: A reversible cause of" exact="heart" post="failureESC Heart Fail.2018537237510.1002/ehf2.12276 108.TonnesmannE.KandolfR.LewalterT.Chloroquine cardiomyopathyâ€&quot;A review of the literatureImmunopharmacol."/>
  <result pre="April 2020) 107.YogasundaramH.HungW.PatersonI.D.SergiC.OuditG.Y.Chloroquine-induced cardiomyopathy: A reversible cause of heart failureESC" exact="Heart" post="Fail.2018537237510.1002/ehf2.12276 108.TonnesmannE.KandolfR.LewalterT.Chloroquine cardiomyopathyâ€&quot;A review of the literatureImmunopharmacol. Immunotoxicol.20133543444210.3109/08923973.2013.78007823635029 109.collab:"/>
  <result pre="Heart Fail.2018537237510.1002/ehf2.12276 108.TonnesmannE.KandolfR.LewalterT.Chloroquine cardiomyopathyâ€&quot;A review of the literatureImmunopharmacol. Immunotoxicol.20133543444210.3109/08923973.2013.78007823635029 109.collab:" exact="American" post="College of CardiologyVentricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment"/>
  <result pre="review of the literatureImmunopharmacol. Immunotoxicol.20133543444210.3109/08923973.2013.78007823635029 109.collab: American College of CardiologyVentricular" exact="Arrhythmia" post="Risk Due to Hydroxychloroquine-Azithromycin Treatment for COVID-19Available online: https://www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ventricular-arrhythmia-risk-due-to-hydroxychloroquine-azithromycin-treatment-for-covid-19(accessed"/>
  <result pre="https://www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ventricular-arrhythmia-risk-due-to-hydroxychloroquine-azithromycin-treatment-for-covid-19(accessed on 25 April 2020) 110.Corrales-MedinaV.F.AlvarezK.N.WeissfeldL.A.AngusD.C.ChirinosJ.A.ChangC.C.NewmanA.LoehrL.FolsomA.R.ElkindM.S.et al.Association between hospitalization for" exact="pneumonia" post="and subsequent risk of cardiovascular diseaseJAMA201531326427410.1001/jama.2014.1822925602997 Figure 1 Potential"/>
  <result pre="110.Corrales-MedinaV.F.AlvarezK.N.WeissfeldL.A.AngusD.C.ChirinosJ.A.ChangC.C.NewmanA.LoehrL.FolsomA.R.ElkindM.S.et al.Association between hospitalization for pneumonia and subsequent risk of" exact="cardiovascular" post="diseaseJAMA201531326427410.1001/jama.2014.1822925602997 Figure 1 Potential Mechanisms of Cardiovascular Complication Caused"/>
  <result pre="1 Potential Mechanisms of Cardiovascular Complication Caused by COVID-19. ARDS," exact="acute" post="respiratory distress syndrome; COVID-19, coronavirus disease 2019; CV, cardiovascular."/>
  <result pre="Potential Mechanisms of Cardiovascular Complication Caused by COVID-19. ARDS, acute" exact="respiratory" post="distress syndrome; COVID-19, coronavirus disease 2019; CV, cardiovascular. Images"/>
  <result pre="Caused by COVID-19. ARDS, acute respiratory distress syndrome; COVID-19, coronavirus" exact="disease" post="2019; CV, cardiovascular. Images were adapted from smart.servier.com by"/>
  <result pre="1Table 1 Prevalence of Cardiovascular Risk Factors and Underlying Cardiovascular" exact="Disease" post="in COVID-19 Patients. Age Cardiovascular Disease Coronary Artery Disease"/>
  <result pre="Factors and Underlying Cardiovascular Disease in COVID-19 Patients. Age Cardiovascular" exact="Disease" post="Coronary Artery Disease Hypertension Diabetes Chronic Kidney Disease Current"/>
  <result pre="Cardiovascular Disease in COVID-19 Patients. Age Cardiovascular Disease Coronary Artery" exact="Disease" post="Hypertension Diabetes Chronic Kidney Disease Current Smoker Chen et"/>
  <result pre="Disease in COVID-19 Patients. Age Cardiovascular Disease Coronary Artery Disease" exact="Hypertension" post="Diabetes Chronic Kidney Disease Current Smoker Chen et al."/>
  <result pre="in COVID-19 Patients. Age Cardiovascular Disease Coronary Artery Disease Hypertension" exact="Diabetes" post="Chronic Kidney Disease Current Smoker Chen et al. 2020"/>
  <result pre="COVID-19 Patients. Age Cardiovascular Disease Coronary Artery Disease Hypertension Diabetes" exact="Chronic" post="Kidney Disease Current Smoker Chen et al. 2020 (n"/>
  <result pre="Patients. Age Cardiovascular Disease Coronary Artery Disease Hypertension Diabetes Chronic" exact="Kidney" post="Disease Current Smoker Chen et al. 2020 (n ="/>
  <result pre="Age Cardiovascular Disease Coronary Artery Disease Hypertension Diabetes Chronic Kidney" exact="Disease" post="Current Smoker Chen et al. 2020 (n = 99)"/>
  <result pre="(%), mean Â± SD, or median (interquartile range); COVID-19, coronavirus" exact="disease" post="2019; ICU: intensive care unit; SD, standard deviation. *"/>
  <result pre="ICU: intensive care unit; SD, standard deviation. * Composite of" exact="cardiovascular" post="and cerebrovascular diseases. jcm-09-01407-t002_Table 2Table 2 Prevalence of Cardiovascular"/>
  <result pre="and cerebrovascular diseases. jcm-09-01407-t002_Table 2Table 2 Prevalence of Cardiovascular Complications," exact="Acute" post="Respiratory Distress Syndrome (ARDS), and Extracorporeal Membrane Oxygenation (ECMO)"/>
  <result pre="cerebrovascular diseases. jcm-09-01407-t002_Table 2Table 2 Prevalence of Cardiovascular Complications, Acute" exact="Respiratory" post="Distress Syndrome (ARDS), and Extracorporeal Membrane Oxygenation (ECMO) in"/>
  <result pre="jcm-09-01407-t002_Table 2Table 2 Prevalence of Cardiovascular Complications, Acute Respiratory Distress" exact="Syndrome" post="(ARDS), and Extracorporeal Membrane Oxygenation (ECMO) in COVID-19 Patients."/>
  <result pre="Extracorporeal Membrane Oxygenation (ECMO) in COVID-19 Patients. Age Myocardial Injury" exact="Arrhythmia" post="Heart Failure Shock ARDS ECMO Chen et al. 2020"/>
  <result pre="Membrane Oxygenation (ECMO) in COVID-19 Patients. Age Myocardial Injury Arrhythmia" exact="Heart Failure" post="Shock ARDS ECMO Chen et al. 2020 (n ="/>
  <result pre="Oxygenation (ECMO) in COVID-19 Patients. Age Myocardial Injury Arrhythmia Heart" exact="Failure" post="Shock ARDS ECMO Chen et al. 2020 (n ="/>
  <result pre="(ECMO) in COVID-19 Patients. Age Myocardial Injury Arrhythmia Heart Failure" exact="Shock" post="ARDS ECMO Chen et al. 2020 (n = 99)"/>
  <result pre="0% Guo et al. 2020 (n = 187) [38]Elevated vs." exact="Normal" post="TnT 59 Â± 15 52 (27.8%)NA 11 (5.9%) â€"/>
  <result pre="n (%), mean Â± SD, or median (interquartile range); ARDS:" exact="acute" post="respiratory distress syndrome; ECMO: extracorporeal membrane oxygenation; ICU: intensive"/>
  <result pre="(%), mean Â± SD, or median (interquartile range); ARDS: acute" exact="respiratory" post="distress syndrome; ECMO: extracorporeal membrane oxygenation; ICU: intensive care"/>
  <result pre="intensive care unit; NA: not applicable; TnT: Troponin T. *" exact="septic shock." post="â€ ventricular tachycardia/ventricular fibrillation."/>
 </snippets>
</snippetsTree>
